2024
Renal Cell Carcinoma of Variant Histology: New Biologic Understanding Leads to Therapeutic Advances.
Salgia N, Zengin Z, Pal S, Dizman N. Renal Cell Carcinoma of Variant Histology: New Biologic Understanding Leads to Therapeutic Advances. American Society Of Clinical Oncology Educational Book 2024, 44: e438642. PMID: 38776514, PMCID: PMC11235416, DOI: 10.1200/edbk_438642.Peer-Reviewed Original ResearchConceptsRenal cell carcinomaPapillary renal cell carcinomaBiology of renal cell carcinomaHistology renal cell carcinomaPatient populationRenal cell carcinoma histologyMetastatic renal cell carcinomaRenal cell carcinoma casesOptimization of treatment regimensNon-clear cellPrecision oncology approachesDiagnosed solid tumorsSarcomatoid dedifferentiationVariant histologyRare subtypeHistopathological subtypesCell carcinomaSolid tumorsClinical featuresTreatment regimensClinical findingsOncology approachesTherapeutic advancesTherapeutic approachesUnique pathogeneses
2022
Association between TERT promoter mutations and clinical outcome with immune checkpoint inhibitor therapy for advanced urothelial cancer.
Chawla N, Tripathi N, Sayegh N, Govindarajan A, Dizman N, Zengin Z, Meza L, Muddasani R, Chehrazi-Raffle A, Salgia S, Malhotra J, Hsu J, Philip E, Bergerot C, Lyou Y, Swami U, Gupta S, Maughan B, Agarwal N, Pal S. Association between TERT promoter mutations and clinical outcome with immune checkpoint inhibitor therapy for advanced urothelial cancer. Journal Of Clinical Oncology 2022, 40: 561-561. DOI: 10.1200/jco.2022.40.6_suppl.561.Peer-Reviewed Original ResearchProgression-free survivalObjective response rateImmune checkpoint inhibitorsICI therapyOverall survivalTERT promoter mutationsBladder cancerFirst-line ICI therapyImmune checkpoint inhibitor therapyAdvanced urothelial cancerSubsequent-line therapyUpper tract diseaseCheckpoint inhibitor therapySuperior overall survivalMetastatic bladder cancerMuscle-invasive diseaseTertiary cancer centerRoutine clinical careCancer Genome Atlas (TCGA) databaseLarge independent cohortsPromoter mutationsTERT mutation statusCheckpoint inhibitorsMetastatic settingVariant histology